Skip to main content
    S

    Silexion Therapeutics Corp (SLXN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.76
    -0.22 (-11.11%)

    Market Cap: $1.29M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Silexion Therapeutics Corp (SLXN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Silexion Therapeutics (SLXN) to earn -$112.80 per share in the fiscal year ending Dec 31, 2026. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$44.16.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$112.80
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$44.16
    EPS consensus

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$112.80-$112.80 to -$112.801
    Dec 31, 2027-$44.16-$44.16 to -$44.161

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.72N/A3

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$127.44.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$112.80-$116.28-$116.28-$119.76-$127.44N/A
    Fiscal year ending Dec 31, 2027-$44.16-$48.60-$48.60-$446.52-$444.36N/A

    Frequently Asked Questions About SLXN

    What is the SLXN stock forecast?

    Consensus analyst estimates put Silexion Therapeutics's EPS at -$112.80 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from SLXN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$112.80, with estimates from -$112.80 to -$112.80 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$44.16, with estimates from -$44.16 to -$44.16 from 1 analyst.

    How many analysts cover SLXN?

    1 analyst estimates EPS for Silexion Therapeutics for the fiscal year ending Dec 31, 2026.